March 02, 2015 6:14 PM ET

Pharmaceuticals

Company Overview of KAEL-GemVax Co., Ltd.

Company Overview

KAEL-GemVax Co., Ltd. develops cancer vaccines and anti-inflammation drugs. Its products include GV1001, an epitope vaccine to ensure that the immune system encounters a sufficient number of the epitopes against which an immune response is desired, and encounters them in the right way for the desired immune response to actually begin; and novel peptide-based anti-inflammatory therapeutic drugs to provide cures for various inflammatory diseases. KAEL-GemVax Co., Ltd. was formerly known as GemVax Co., Ltd. The company was founded in 2001 and is based in Seongam-si, South Korea. KAEL-GemVax Co., Ltd. operates as a subsidiary of GemVax & Kael Co., Ltd.

3rd Floor GemVax Tower

146 Unjung-ro

Bundang-gu

Seongam-si,  463-440

South Korea

Founded in 2001

Phone:

82 2 544 6221

Fax:

82 2 3443 4997

Key Executives for KAEL-GemVax Co., Ltd.

Chief Executive Officer and President
Founder, Chairman, President and CRO
Chief Executive Officer of USA
Age: 75
Senior Vice President
Compensation as of Fiscal Year 2014.

Similar Private Companies By Industry

Company Name Region
Lilly Korea Ltd. Asia
Botamedi, Inc. Asia
Won Gwang Bio Asia
Choongwae Shin-Yak Corporation Asia
Alvogen Korea Ltd. Asia

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact KAEL-GemVax Co., Ltd., please visit www.kaelgemvax.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.